Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Activated protein C has a regulatory role in factor VIII function

Amelia R. Wilhelm, Nicole A. Parsons, Benjamin J. Samelson-Jones, Robert J. Davidson, Charles T. Esmon, Rodney M. Camire, Lindsey A. George

Blood (2021) 137 (18): 2532–2543.

https://doi.org/10.1182/blood.2020007562

Published: 2021

Includes: Supplemental data

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Journal Articles

Cofactor and Cofactor Mimetics

Peter J. Lenting, PhD

Blood (2019) 134 (Supplement_1): SCI-17.

https://doi.org/10.1182/blood-2019-121059

Published: 2019

Journal Articles

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

Amelia R. Wilhelm, B.S., Nicole A. Parsons, B.S., Charles T. Esmon, PhD, Rodney M. Camire, PhD, Lindsey A. George, MD

Blood (2019) 134 (Supplement_1): 93.

https://doi.org/10.1182/blood-2019-124493

Published: 2019

Journal Articles

The Complete Dependence of Factor IX Padua (R338L) Hyperactivity on Factor VIIIa Cofactor Activity Supports Its Safety As a Transgene for Hemophilia B Gene Therapy

Benjamin J. Samelson-Jones, MD PhD, John D. Finn, PhD, Rodney M. Camire, PhD, Valder R Arruda, MD PhD

Blood (2018) 132 (Supplement 1): 3486.

https://doi.org/10.1182/blood-2018-99-119270

Published: 2018

Journal Articles

Activated Factor IX As a Candidate for the Initial Protease in the Coagulation Cascade

Tina M Misenheimer, PhD, Kraig T Kumfer, MD PhD, Barbara E Bates, MS, Brad S Schwartz, MD

Blood (2017) 130 (Supplement 1): 235.

https://doi.org/10.1182/blood.V130.Suppl_1.235.235

Published: 2017

Journal Articles

Targeting Factor Xa Expression in Platelets As a Potential Gene Therapy Strategy for Hemophilia with Inhibitors

Dawei Wang, Xiaohu Shao, Guowei Zhang, PhD, Shuxian Yao, Xielai Zhou, Jianhua Mao, PhD, Zhugang Wang, Zhu Chen, Saijuan Chen

Blood (2016) 128 (22): 1171.

https://doi.org/10.1182/blood.V128.22.1171.1171

Published: 2016

Journal Articles

Rivaroxaban Prophylaxis in Severe Congenital Protein C Deficiency

Gabriel Salinas Cisneros, MD, Ziad Khatib, MD

Blood (2016) 128 (22): 4945.

https://doi.org/10.1182/blood.V128.22.4945.4945

Published: 2016

Journal Articles

Aptamer Mediated Inhibition of Protein S

William E. Plautz, Juliana Layzer, PhD, Bruce A. Sullenger, PhD, Rinku Majumder, PhD

Blood (2016) 128 (22): 4946.

https://doi.org/10.1182/blood.V128.22.4946.4946

Published: 2016

Journal Articles

TFPIα Has Reduced Ability to Inhibit FV Leiden

Jeremy P. Wood, PhD, Lisa Baumann Kreuziger, MD, Rodney M. Camire, PhD, Alan E. Mast, MD PhD

Blood (2015) 126 (23): 423.

https://doi.org/10.1182/blood.V126.23.423.423

Published: 2015

Journal Articles

Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models

Lilley Leong, Derek Sim, Chandra Patel, Katherine Tran, Perry Liu, Elena Ho, Thomas Thompson, Peter J. Kretschmer, Hironao Wakabayashi, Philip J. Fay, John E. Murphy

Blood (2015) 125 (2): 392–398.

https://doi.org/10.1182/blood-2014-02-555656

Published: 2015

Includes: Supplemental data

Journal Articles

X-Ray Structure of an Anticoagulant RNA Aptamer Bound to Factor Xa. Structural Basis for Its Ability to Disrupt Interactions Between Xa and Va within Prothrombinase

Shekhar Kumar, PhD, Bruce A. Sullenger, PhD, Steven Stayrook, PhD, Sriram Krishnaswamy, PhD

Blood (2014) 124 (21): 4232.

https://doi.org/10.1182/blood.V124.21.4232.4232

Published: 2014

Journal Articles

Site-Directed Pegylation of BDD FVIII (BAY 94-9027) Does Not Alter the Ability of the Molecule to Generate Thrombin, Activate Factor X or Become Inactivated By Activated Protein C

Subramanian Yegneswaran, PhD, Xiaoqiao Jiang, BS, Pooja Yesantharao, Ji-Yun Kim, PhD, Lilley Leong, PhD MS, Derek S Sim, PhD, Chandra Patel, PhD, Katalin Zsofia Kauser, PhD MD DSc

Blood (2014) 124 (21): 1492.

https://doi.org/10.1182/blood.V124.21.1492.1492

Published: 2014

Journal Articles

FVIII Heavy Chain Enhances Tenase Activity Induced By FVIIIa Mimicking Bispesific Antibody, ACE910

Hiroaki Minami, MD, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 1481.

https://doi.org/10.1182/blood.V124.21.1481.1481

Published: 2014

Journal Articles

Identification Of The Thrombin-Binding Site On Factor VIII Regulating Arg 372 Cleavage In The Factor VIII Heavy Chain

Hiroaki Minami, MD, Keiji Nogami, MD, PhD, Koji Yada, MD, PhD, Midori Shima, MD, PhD

Blood (2013) 122 (21): 3570.

https://doi.org/10.1182/blood.V122.21.3570.3570

Published: 2013

Journal Articles

Stabilizing Factor VIIIa By Combining Mutations That Modulate Inter-Subunit Interactions and Proteolytic Inactivation

Hironao Wakabayashi, MD, PhD, Jennifer Wintermute, Philip J. Fay, PhD

Blood (2013) 122 (21): 3572.

https://doi.org/10.1182/blood.V122.21.3572.3572

Published: 2013

Journal Articles

Thrombin-Stimulated Platelets Have Functional Binding Sites For Factor VIIIa That Are Distinct From Phosphatidylserine

Jialan Shi, PhD, Valerie A Novakovic, M.S., Steven Pipe, Shannon Meeks, M.D., John (Pete) S. Lollar, MD, Stephanie A. Smith, DVM, MS, James H. Morrissey, PhD, Gary E. Gilbert, M.D.

Blood (2013) 122 (21): 3582.

https://doi.org/10.1182/blood.V122.21.3582.3582

Published: 2013

Journal Articles

Antibody ESH4, Against the Factor VIII C2 Domain, Causes a Remote Change near the Factor IXa Active Site and Inhibition That Is Related to Membrane Composition

Valerie A Novakovic, M.S., Junhong Lu, Ph.D., Gary E. Gilbert, M.D.

Blood (2012) 120 (21): 3355.

https://doi.org/10.1182/blood.V120.21.3355.3355

Published: 2012

Journal Articles

Factor VIII Region 1811–1818 Is Involved in Factor IXa Binding and Factor VIIIa Stability

Esther Bloem, Msc, Henriet Meems, PhD, Maartje van den Biggelaar, PhD, Koen Mertens, PhD, Alexander B Meijer, PhD

Blood (2012) 120 (21): 3357.

https://doi.org/10.1182/blood.V120.21.3357.3357

Published: 2012

NARROW

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Activated protein C has a regulatory role in factor VIII function

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Cofactor and Cofactor Mimetics

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

The Complete Dependence of Factor IX Padua (R338L) Hyperactivity on Factor VIIIa Cofactor Activity Supports Its Safety As a Transgene for Hemophilia B Gene Therapy

Activated Factor IX As a Candidate for the Initial Protease in the Coagulation Cascade

Targeting Factor Xa Expression in Platelets As a Potential Gene Therapy Strategy for Hemophilia with Inhibitors

Rivaroxaban Prophylaxis in Severe Congenital Protein C Deficiency

Aptamer Mediated Inhibition of Protein S

TFPIα Has Reduced Ability to Inhibit FV Leiden

Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models

X-Ray Structure of an Anticoagulant RNA Aptamer Bound to Factor Xa. Structural Basis for Its Ability to Disrupt Interactions Between Xa and Va within Prothrombinase

Site-Directed Pegylation of BDD FVIII (BAY 94-9027) Does Not Alter the Ability of the Molecule to Generate Thrombin, Activate Factor X or Become Inactivated By Activated Protein C

FVIII Heavy Chain Enhances Tenase Activity Induced By FVIIIa Mimicking Bispesific Antibody, ACE910

Identification Of The Thrombin-Binding Site On Factor VIII Regulating Arg 372 Cleavage In The Factor VIII Heavy Chain

Stabilizing Factor VIIIa By Combining Mutations That Modulate Inter-Subunit Interactions and Proteolytic Inactivation

Thrombin-Stimulated Platelets Have Functional Binding Sites For Factor VIIIa That Are Distinct From Phosphatidylserine

Antibody ESH4, Against the Factor VIII C2 Domain, Causes a Remote Change near the Factor IXa Active Site and Inhibition That Is Related to Membrane Composition

Factor VIII Region 1811–1818 Is Involved in Factor IXa Binding and Factor VIIIa Stability

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only